Bruce L.A. Carter Ph.D. Joins Biothera Board of Directors
EAGAN, Minn.--(BUSINESS WIRE)--Biothera announced today the appointment of Bruce L.A. Carter, Ph.D. to its board of directors.
“I’m thoroughly impressed with the mechanism of action, the safety profile and the clinical data of Imprime PGG.”
“Dr. Carter’s scientific expertise and executive management experience, particularly in pharmaceutical strategy and M&A, will be invaluable to Biothera,” said Dan Conners, Biothera chairman of the board.
“I’ve been in this industry a long time and I’m excited about Biothera’s truly novel approach to the treatment of cancer,” said Dr. Carter. “I’m thoroughly impressed with the mechanism of action, the safety profile and the clinical data of Imprime PGG.”
Dr. Carter has extensive experience in the pharmaceutical industry. He served as President of ZymoGenetics, Inc. from 1988 to 1994 when Novo Nordisk acquired the company. At Novo Nordisk, Dr. Carter was Corporate Executive Vice President and Chief Scientific Officer until 2000 when he led a buyout of ZymoGenetics. He was named President and Chief Executive Officer of the independent company and led ZymoGenetics’ successful development and commercialization of Recothrom®, a recombinant thrombin for use during surgical procedures. Bristol-Myers Squibb acquired ZymoGenetics in 2008.
More recently, Dr. Carter was Executive Chairman of Immune Design Corp. from 2009 to 2011. He currently serves as a director of several publicly traded companies: Dr. Reddy’s Laboratories Ltd., Enanta Pharmaceuticals, Inc., Regulus Therapeutics, Inc. and Xencor, Inc.
Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
About Biothera, the Immune Health Company
Biothera is a U.S. biotechnology company dedicated to improving immune health. The company’s Pharmaceutical business is developing Imprime PGG®, a Phase 3 immunotherapy that engages and directs neutrophils and monocytes to kill cancer. This targeted mechanism is synergistic with multiple anti-tumor monoclonal antibodies, providing the potential to improve patient outcomes in a wide range of cancer indications, including colorectal cancer, non-small cell lung cancer and chronic lymphocytic leukemia. Biothera’s Healthcare business manufactures and markets Wellmune WGP® and other natural, clinically proven immune health ingredients for foods, beverages and supplements in more than 60 countries.
For more information, visit our website at www.biothera.com.